116 related articles for article (PubMed ID: 34273805)
1. White blood cell subsets in HER2-positive breast cancer patients treated with trastuzumab in relation to clinical outcome.
Matić IZ; Grujić M; Kolundžija B; Damjanović A; Tomašević Z; Đorđić Crnogorac M; Džodić R; Filipović Lješković I; Ždrale Z; Erić-Nikolić A; Juranić Z
Pathol Res Pract; 2021 Aug; 224():153543. PubMed ID: 34273805
[TBL] [Abstract][Full Text] [Related]
2. Peripheral White Blood Cell Subsets in Metastatic Colorectal Cancer Patients Treated with Cetuximab: The Potential Clinical Relevance.
Matić IZ; Kolundžija B; Damjanović A; Spasić J; Radosavljević D; Đorđić Crnogorac M; Grozdanić N; Juranić ZD
Front Immunol; 2017; 8():1886. PubMed ID: 29354119
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy.
Murta EF; de Andrade JM; Falcão RP; Bighetti S
Tumori; 2000; 86(5):403-7. PubMed ID: 11130570
[TBL] [Abstract][Full Text] [Related]
4. [Percentages and functions of natural killer cell subsets in peripheral blood of patients with severe aplastic anemia].
Li ZS; Shao ZH; Fu R; Wang J; Li LJ; Zhang T; Wang HQ; Wu YH; Ruan EB; Song J; Qu W; Liu H; Xing LM; Wang XM; Liang Y; Guan J; Wang GJ
Zhonghua Yi Xue Za Zhi; 2011 Apr; 91(16):1084-7. PubMed ID: 21609587
[TBL] [Abstract][Full Text] [Related]
5. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
[TBL] [Abstract][Full Text] [Related]
6. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
Varchetta S; Gibelli N; Oliviero B; Nardini E; Gennari R; Gatti G; Silva LS; Villani L; Tagliabue E; Ménard S; Costa A; Fagnoni FF
Cancer Res; 2007 Dec; 67(24):11991-9. PubMed ID: 18089830
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer.
Miura D; Yoneyama K; Furuhata Y; Shimizu K
J Nippon Med Sch; 2014; 81(4):211-20. PubMed ID: 25186575
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic profiles of peripheral blood lymphocytes on the day of embryo transfer in women undergoing in vitro fertilization.
Baczkowski T; Kurzawa R
Folia Histochem Cytobiol; 2007; 45 Suppl 1():S73-7. PubMed ID: 18292839
[TBL] [Abstract][Full Text] [Related]
9. Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida.
Valiathan R; Deeb K; Diamante M; Ashman M; Sachdeva N; Asthana D
Immunobiology; 2014 Jul; 219(7):487-96. PubMed ID: 24661720
[TBL] [Abstract][Full Text] [Related]
10. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
11. Diurnal redistribution of human lymphocytes and their temporal associations with salivary cortisol.
Trifonova ST; Zimmer J; Turner JD; Muller CP
Chronobiol Int; 2013 Jun; 30(5):669-81. PubMed ID: 23688120
[TBL] [Abstract][Full Text] [Related]
12. [Changes and clinical significance of peripheral blood natural killer cells in neonates with bacterial pneumonia].
Li Q; Weng K; Zhu L; Mei X; Xu L; Lin J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Oct; 30(10):1067-70. PubMed ID: 25270210
[TBL] [Abstract][Full Text] [Related]
13. NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.
Santana-Hernández S; Suarez-Olmos J; Servitja S; Berenguer-Molins P; Costa-Garcia M; Comerma L; Rea A; Perera-Bel J; Menendez S; Arpí O; Bermejo B; Martínez MT; Cejalvo JM; Comino-Méndez I; Pascual J; Alba E; López-Botet M; Rojo F; Rovira A; Albanell J; Muntasell A
J Exp Clin Cancer Res; 2024 Jan; 43(1):10. PubMed ID: 38167224
[TBL] [Abstract][Full Text] [Related]
14. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients.
Suzuki E; Kataoka TR; Hirata M; Kawaguchi K; Nishie M; Haga H; Toi M
BMC Cancer; 2015 Feb; 15():39. PubMed ID: 25655677
[TBL] [Abstract][Full Text] [Related]
15. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
[TBL] [Abstract][Full Text] [Related]
16. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
17. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer.
Horlock C; Stott B; Dyson PJ; Morishita M; Coombes RC; Savage P; Stebbing J
Br J Cancer; 2009 Apr; 100(7):1061-7. PubMed ID: 19277040
[TBL] [Abstract][Full Text] [Related]
18. Effect of dietary ribonucleotides on infant immune status. Part 2: Immune cell development.
Buck RH; Thomas DL; Winship TR; Cordle CT; Kuchan MJ; Baggs GE; Schaller JP; Wheeler JG
Pediatr Res; 2004 Dec; 56(6):891-900. PubMed ID: 15496603
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional human CD56 low CD16 low natural killer cells are the prominent subset in bone marrow of both healthy pediatric donors and leukemic patients.
Stabile H; Nisti P; Morrone S; Pagliara D; Bertaina A; Locatelli F; Santoni A; Gismondi A
Haematologica; 2015 Apr; 100(4):489-98. PubMed ID: 25596273
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients.
Petricevic B; Laengle J; Singer J; Sachet M; Fazekas J; Steger G; Bartsch R; Jensen-Jarolim E; Bergmann M
J Transl Med; 2013 Dec; 11():307. PubMed ID: 24330813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
